Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ingredient Safety Concerns Rise Among FDA Enforcement Priorities

This article was originally published in The Tan Sheet

Executive Summary

Ingredient safety, new dietary ingredient notifications, adverse event reporting, claims substantiation and disease claims are all drawing FDA attention in the supplement space, Daniel Fabricant says. Compliance for good manufacturing practices still heads the priorities for enforcement, he says.


Related Content

Medical Foods No “Dumping Ground” For Disease Claims – FDA
In Brief: FDA responds to Nasacort suit, acts on acetaminophen and continues medical food enforcement
USP “Fingerprint” Library Aims To Fortify Product Safety
Dendrobium, PEA Supplements Carry Risks For Manufacturers
USP “Fingerprint” Library Aims To Fortify Product Safety
FDA NDI Draft Is A Push For Tighter Supplement Regulation – Stakeholders
Energy Drinks Swayed By Liquid Supplement Draft Guidance After All
OIG Report on Supplement Claims Finds Disease Claims, Substantiation Issues
Supplement Ingredient Supply Trends Can Shed Light On Adulteration
Kava Labeling Revisions Adopted By Trade Groups; FDA Issues Advisory





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts